

The Menopause Transition: Optimally Protecting Emotional Health

Rachel Franklin, MD, FAAFP

Content Courtesy of NIAFP



OKLAHOMA ACADEMY OF
FAMILY PHYSICIANS
2023 SCIENTIFIC ASSEMBLY

Credit to Original Authors

Gloria Bachmann, MD

Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences
Associate Dean of Women's Health and Director, Women's Health Institute
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Jeffrey P. Levine, MD, MPH

Professor and Director of Reproductive & Gender Health Programs
Department of Family Medicine and Community Health
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Nancy A. Phillips, MD

Associate Professor, Department of Obstetrics, Gynecology, and Reproductive Services
Director, Center of Vulvovaginal Health
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Disclosures

- Neither the original authors or I have any relevant financial relationship(s) to disclose

Learning Objectives

- Recognize that in the clinical setting, women from different ethnic backgrounds may characterize menopause and its associated symptoms differently
- Employ patient-focused, culturally relevant communication techniques when counseling patients regarding menopause and their menopausal symptoms
- Utilize a patient-centered, shared-decision making approach in the evaluation and management of menopausal symptoms, including depression
- Provide objective, up-to-date, evidence-based education regarding possible menopausal symptom treatment options along with an individualized management and follow-up plan



Pre-test: Question 1

Menopause is defined as the complete cessation of menses for

- 9 months
- 12 months
- 18 months
- 24 months



Pre-test: Question 2

2. What percentage of women will experience vasomotor symptoms during the menopausal transition, with the majority rating their symptoms as moderate to severe?

- 50%
- 60%
- 70%
- 89%



Pre-test: Question 3

Which two actions can help uncover whether menopausal symptoms are leading to a patient's depression or depression is exacerbating the menopausal symptoms?

- a. Patient history and laboratory results
- b. History of depression and past medications
- c. Patient history and motivational interviewing
- d. Motivational interviewing and laboratory results



Pre-test: Question 4

There is evidence that perimenopausal fluctuations in which hormone increases a menopausal woman's sensitivity to psychosocial stress and increases her vulnerability to depression?

- a. Estradiol
- b. Progesterone
- c. Testosterone
- d. Follicle-stimulating hormone





Menopause: Introduction

9

Transition to Menopause

- Menopause—the complete cessation of menses for 12 months
 - Average age in US is 51
 - Can range from 45 to 55 years
- Near-complete loss of estrogen production results in endocrinological, physical, and psychological changes which occur over years
- Symptoms range
 - Mild/moderate to severe/disabling discomfort
 - Influenced by physiologic, psychological, ethnic, and socio-cultural factors
- The average lifespan of a woman in the US is now 81 yrs old - most women can expect to spend about 30 years (almost 40%) of their lifetime post-menopausal

Talaulkar Best Pract Res Clin Obstet Gynaecol 2022;81:3-7 | Goodman Endocrine Practice. 2011;17:1-25.

The Stages of Reproductive Aging

	Menarche					FMP (M)			
Stage	5	4	3	2	1	1	2	3	4
Terminology	REPRODUCTIVE				MENOPAUSAL TRANSITION				POST-MENOPAUSE
	Early	Peak	Late		Early	Late	Early	Late	
Duration	variable				variable				variable
PRINCIPAL CRITERIA									
Menstrual Cycle	Variable to regular	Regular	Regular	Variable changes in length	Variable Length Persistent 27-day difference in length of consecutive cycles	Interval of approximately 60-90 days			
SUPPORTIVE CRITERIA									
Endocrine									
FSH		Low	Variable*	↑ Variable*	↑ >25 IU/L**	Variable	Stable		
AMH		Low	Low	Low	Low	Low	Very Low		
Anti-Müllerian Hormone		Low	Low	Low	Low	Very Low	Very Low		
DESCRIPTIVE CHARACTERISTICS									
Symptoms									
						Vasomotor symptoms (Hot)	Vasomotor symptoms (Hot)	Increasing symptoms of osteoporosis	

* Blood draw on cycle days 2-5 ** - elevated

** Approximate expected level based on assays using current international puberty standard¹⁴

J Clin Endocrinol Metab, Volume 97, Issue 4, 1 April 2012, Pages 1159–1168



Menopausal Transition: Signs and Symptoms

Signs and Symptoms of the Menopausal Transition that Women may Report

- Irregular bleeding
- Vasomotor symptoms
 - Hot flushes and/or night sweats
- Genitourinary Syndrome of Menopause
 - Dryness
 - Recurrent urinary tract infections
 - Dyspareunia
- Sweating
- Dizzy spells
- Palpitations
- Headache
- Decreased sexual desire
- Insomnia
- Fatigue
- Difficulty concentrating
- Mood Changes
 - Irritability
 - Anxiety
 - Depression



Symptoms

- Risk factors impacting the frequency/severity of vasomotor symptoms:
 - Menopausal status
 - Race
 - Smoking
 - Overweight/Obesity
 - Antiestrogen therapy
 - Anxiety or depression prior to menopause
- Over 80% of women will experience vasomotor symptoms during the menopausal transition, with the majority rating them as moderate to severe.
- Clinical symptoms of menopause can have a major impact on a woman's life and are the main reason for their seeking treatment



Factors Impacting Vasomotor Symptoms

- African American women and Hispanic women have hot flushes for longer periods of time than white or Asian-American women
- Smoking and passive smoke exposure are significant factors in the intensity of vasomotor symptoms
- Current smokers are over 60% more likely to report vasomotor symptoms than non-smokers
- Overweight and obesity are also associated with more severe vasomotor symptoms during pre- and perimenopause period
- GnRH agonists/antagonists; aromatase inhibitors, and certain SERMs often lead to moderate to severe vasomotor symptoms





Depression During the Menopausal Transition

16

Depression During the Menopausal Transition

- Depression
 - More common during the menopausal transition, even in women with no history of depression
 - Treatment may not be as straightforward as depression presenting at other times
- Women with a history of depression are 13 times more likely to exhibit depressive symptoms during the menopausal transition
- 28% to 47% of women without a history of depression reported experiencing depressive symptoms during perimenopause
- Perimenopausal estradiol fluctuations increase a woman's sensitivity to psychosocial stress and her vulnerability to depression.

Freeman Archives of General Psychiatry. 2004;61(11):62-70. | Bromberger Archives of General Psychiatry. 2010;67(6):598-607. | Maki Menopause. 2013;25(10):1069-1085. | Shea Journal of Obstetrics and Gynecology Canada. 2002;43(11):1316-1322. | Freeman JAMA Psychiatry. 2014;71(1):36-43. | Maki Journal of Women's Health. 2019;28(2):117-134.



Depression During the Menopausal Transition

- It is important to distinguish between menopausal symptoms and underlying depression
- Hormonal changes can
 - Lead to depressive symptoms
 - Lead to overt depression
 - Exacerbate existing symptoms of depression
 - Reactivate previous major depression
 - Cause depression or depressive symptoms secondary to distressing menopausal symptoms



Table 1. Relative risk of major adverse events in women using hormone therapy (HT) compared with nonusers, by age, duration of use, and type of HT.

Event	Age (years)	Duration (years)	Relative risk (95% CI)
Stroke	50-59	<5	1.0 (0.8-1.2)
Stroke	60-69	<5	1.0 (0.8-1.2)
Stroke	70-79	<5	1.0 (0.8-1.2)
Stroke	80-89	<5	1.0 (0.8-1.2)
Stroke	90-99	<5	1.0 (0.8-1.2)
Stroke	50-59	5-9	1.0 (0.8-1.2)
Stroke	60-69	5-9	1.0 (0.8-1.2)
Stroke	70-79	5-9	1.0 (0.8-1.2)
Stroke	80-89	5-9	1.0 (0.8-1.2)
Stroke	90-99	5-9	1.0 (0.8-1.2)
Stroke	50-59	10-14	1.0 (0.8-1.2)
Stroke	60-69	10-14	1.0 (0.8-1.2)
Stroke	70-79	10-14	1.0 (0.8-1.2)
Stroke	80-89	10-14	1.0 (0.8-1.2)
Stroke	90-99	10-14	1.0 (0.8-1.2)
Stroke	50-59	15-19	1.0 (0.8-1.2)
Stroke	60-69	15-19	1.0 (0.8-1.2)
Stroke	70-79	15-19	1.0 (0.8-1.2)
Stroke	80-89	15-19	1.0 (0.8-1.2)
Stroke	90-99	15-19	1.0 (0.8-1.2)
Stroke	50-59	20-24	1.0 (0.8-1.2)
Stroke	60-69	20-24	1.0 (0.8-1.2)
Stroke	70-79	20-24	1.0 (0.8-1.2)
Stroke	80-89	20-24	1.0 (0.8-1.2)
Stroke	90-99	20-24	1.0 (0.8-1.2)
Stroke	50-59	25-29	1.0 (0.8-1.2)
Stroke	60-69	25-29	1.0 (0.8-1.2)
Stroke	70-79	25-29	1.0 (0.8-1.2)
Stroke	80-89	25-29	1.0 (0.8-1.2)
Stroke	90-99	25-29	1.0 (0.8-1.2)
Stroke	50-59	30-34	1.0 (0.8-1.2)
Stroke	60-69	30-34	1.0 (0.8-1.2)
Stroke	70-79	30-34	1.0 (0.8-1.2)
Stroke	80-89	30-34	1.0 (0.8-1.2)
Stroke	90-99	30-34	1.0 (0.8-1.2)
Stroke	50-59	35-39	1.0 (0.8-1.2)
Stroke	60-69	35-39	1.0 (0.8-1.2)
Stroke	70-79	35-39	1.0 (0.8-1.2)
Stroke	80-89	35-39	1.0 (0.8-1.2)
Stroke	90-99	35-39	1.0 (0.8-1.2)
Stroke	50-59	40-44	1.0 (0.8-1.2)
Stroke	60-69	40-44	1.0 (0.8-1.2)
Stroke	70-79	40-44	1.0 (0.8-1.2)
Stroke	80-89	40-44	1.0 (0.8-1.2)
Stroke	90-99	40-44	1.0 (0.8-1.2)
Stroke	50-59	45-49	1.0 (0.8-1.2)
Stroke	60-69	45-49	1.0 (0.8-1.2)
Stroke	70-79	45-49	1.0 (0.8-1.2)
Stroke	80-89	45-49	1.0 (0.8-1.2)
Stroke	90-99	45-49	1.0 (0.8-1.2)
Stroke	50-59	50-54	1.0 (0.8-1.2)
Stroke	60-69	50-54	1.0 (0.8-1.2)
Stroke	70-79	50-54	1.0 (0.8-1.2)
Stroke	80-89	50-54	1.0 (0.8-1.2)
Stroke	90-99	50-54	1.0 (0.8-1.2)
Stroke	50-59	55-59	1.0 (0.8-1.2)
Stroke	60-69	55-59	1.0 (0.8-1.2)
Stroke	70-79	55-59	1.0 (0.8-1.2)
Stroke	80-89	55-59	1.0 (0.8-1.2)
Stroke	90-99	55-59	1.0 (0.8-1.2)
Stroke	50-59	60-64	1.0 (0.8-1.2)
Stroke	60-69	60-64	1.0 (0.8-1.2)
Stroke	70-79	60-64	1.0 (0.8-1.2)
Stroke	80-89	60-64	1.0 (0.8-1.2)
Stroke	90-99	60-64	1.0 (0.8-1.2)
Stroke	50-59	65-69	1.0 (0.8-1.2)
Stroke	60-69	65-69	1.0 (0.8-1.2)
Stroke	70-79	65-69	1.0 (0.8-1.2)
Stroke	80-89	65-69	1.0 (0.8-1.2)
Stroke	90-99	65-69	1.0 (0.8-1.2)
Stroke	50-59	70-74	1.0 (0.8-1.2)
Stroke	60-69	70-74	1.0 (0.8-1.2)
Stroke	70-79	70-74	1.0 (0.8-1.2)
Stroke	80-89	70-74	1.0 (0.8-1.2)
Stroke	90-99	70-74	1.0 (0.8-1.2)
Stroke	50-59	75-79	1.0 (0.8-1.2)
Stroke	60-69	75-79	1.0 (0.8-1.2)
Stroke	70-79	75-79	1.0 (0.8-1.2)
Stroke	80-89	75-79	1.0 (0.8-1.2)
Stroke	90-99	75-79	1.0 (0.8-1.2)
Stroke	50-59	80-84	1.0 (0.8-1.2)
Stroke	60-69	80-84	1.0 (0.8-1.2)
Stroke	70-79	80-84	1.0 (0.8-1.2)
Stroke	80-89	80-84	1.0 (0.8-1.2)
Stroke	90-99	80-84	1.0 (0.8-1.2)
Stroke	50-59	85-89	1.0 (0.8-1.2)
Stroke	60-69	85-89	1.0 (0.8-1.2)
Stroke	70-79	85-89	1.0 (0.8-1.2)
Stroke	80-89	85-89	1.0 (0.8-1.2)
Stroke	90-99	85-89	1.0 (0.8-1.2)
Stroke	50-59	90-94	1.0 (0.8-1.2)
Stroke	60-69	90-94	1.0 (0.8-1.2)
Stroke	70-79	90-94	1.0 (0.8-1.2)
Stroke	80-89	90-94	1.0 (0.8-1.2)
Stroke	90-99	90-94	1.0 (0.8-1.2)
Stroke	50-59	95-99	1.0 (0.8-1.2)
Stroke	60-69	95-99	1.0 (0.8-1.2)
Stroke	70-79	95-99	1.0 (0.8-1.2)
Stroke	80-89	95-99	1.0 (0.8-1.2)
Stroke	90-99	95-99	1.0 (0.8-1.2)



Treatment: Recommendations for Clinical Care

20

Re-Evaluating the Safety of Hormone Therapy

- For most symptomatic, healthy women aged 60 or younger or within 10 years of their final period, the benefits of estrogen-containing Hormone Therapy (primarily menopausal symptom management) outweigh the risk (breast cancer, CVD, CVA)
- Few absolute contraindications to the use of estrogen-containing Hormone Therapy in perimenopausal women (i.e., History of VTE, Breast Cancer, Current Smoking, Uncontrolled Hypertension)
- If a woman is extremely symptomatic but does not fit into the category of safely taking HT, consult with a specialist (i.e., oncologist) to discuss options

Recommendations for Clinical Care

Estrogen-containing Hormone Therapy (COCs, ET, or EPT)

- For perimenopausal patients with mood-related symptoms temporally related to menstrual cycle changes and vasomotor symptoms, estrogen therapy may help alleviate both their physical and mood symptoms
- In patients whose mood symptoms do not improve on estrogen-containing Hormone Therapy (HT), consider underlying depression being exacerbated by their physical symptoms
- In patients with confirmed MDD, SSRIs or SNRIs should be used first-line. HT is not indicated for the management of MDD.



Recommendations for Clinical Care

- SSRIs or SNRIs reduce the frequency and severity of hot flashes in menopausal and post-menopausal women
- Most effective SSRIs: paroxetine, citalopram, and escitalopram
- Most effective SNRI: venlafaxine, with desvenlafaxine as a second option
- Most common side effects for both were nausea and constipation, with most resolving within the first week of treatment
- SNRIs have been associated with increased BP in some patients and should be used with caution in women with hypertension
- SSRIs have been shown to interfere with tamoxifen metabolism - SNRIs are the safest drugs for this population



Freeman *Jama Psych*. 2014;71(1):36-43 | Maki *J Women's Health*. 2019;28(2):117-134 | Newhouse *Am Fam Physician*. 2022;105(4):430-431.

Recommendations for Clinical Care

- In patients with severe somatic and emotional symptoms: consider treating their physical symptoms with HT and their mood symptoms with an SSRI or an SNRI
- For moderate to severe vaginal and vulvar symptoms (dyspareunia, vaginal dryness, etc.), low-dose local vaginal estrogen therapy provides safe and highly effective management with low side effects
- For patients with both vasomotor and vulvovaginal symptoms, systemic ET or EPT with or without local vaginal estrogen therapy are effective treatment





Talking with Your Patient

25

Talking With Your Patient

- Proactively asking your patient open-ended questions about perimenopausal symptoms validates what your patient is experiencing and will help get to the underlying cause of the symptoms
- Your patient may not admit to symptoms the first time the questions are asked due to feelings of shame or embarrassment
- Your patient may not know that symptoms they are experiencing are related to the menopause transition and/or that there are treatment and counseling options to help alleviate discomfort



26

Talking With Your Patient

- Have a conversation about what to expect before the average age of perimenopause
- Dispel any myths or misunderstandings
- Indicate that what they are experiencing is very common
- Ask open-ended questions
- Encourage your patient to feel comfortable asking questions
- Consider having their partner involved to get to root of the problem so it can be treated appropriately



27

Talking With Your Patient

- Sociocultural factors to consider
 - How menopause and female aging are viewed culturally
 - The role of family and community
 - Gender norms
- Women who immigrated from their country of origin, especially if there is a language barrier, may have family and friends as their main source of information
- Women experiencing symptoms may be ashamed or embarrassed to ask for advice and support



Talking With Your Patient

- Some suggestions when having a conversation with your patient:
- Reassure them that the symptoms they are experiencing are common and can be managed successfully
 - Use Motivational Interviewing to individualize their treatment goals
 - Use Shared Decision Making to determine an acceptable symptom management and follow-up plan
 - Identify your patient's beliefs, and fears regarding their symptoms
 - Promote effective non-pharmacologic strategies, including smoking cessation
 - Objectively review appropriate medication options
 - Objectively discuss any questions regarding herbal remedies
 - Set realistic expectations
 - Agree on a clear follow-up plan with written instructions
 - Encourage them to contact you with any concerns or questions



Talking With Your Patient

- Dealing with time constraints
- You do not need to address your patient's perimenopausal symptoms in one visit, unless they are experiencing severe depression with suicidal/homicidal ideations
 - Acknowledge your patient's symptoms and their effect on their quality of life
 - Understand it is okay to tell them that you may not be able to address all their perimenopausal symptoms issues at once
 - Inform them that their symptoms may all be related to one condition and instruct them to keep a symptoms diary to assist in the diagnosis
 - Have your patient schedule a follow-up appointment to focus specifically on these symptoms and to discuss treatment options





Life's transitions may be dis-easing, but they are not diseases.



The North American Menopause Society The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news	https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
National Heart, Lung, and Blood Institute Facts About Menopausal Hormone Therapy	https://www.nih.gov/health-information/menopausal-hormone-therapy-information
Journal of Women's Health Guidelines for the Evaluation and Management of Perimenopausal Depression	https://pubmed.ncbi.nlm.nih.gov/30182804/
The Endocrine Society Patient resources about menopause	https://www.endocrine.org/patient-engagement/endocrine-library/menopause



References

1. Aick HE, et al. Vasomotor Symptoms Across the Menopause Transition: Differences Among Women. *Obstet Gynecol Clin North Am*. 2018;45(4):629-640.
2. Blount JC. Communication with Women in the Menopause Transition. Springer; 2022.
3. Borenberger JT, et al. Longitudinal Change in Reproductive Hormones and Depressive Symptoms Across the Menopausal Transition: Results From the Study of Women's Health Across the Nation (SWAN). *Arch Gen Psychiatry*. 2022;79(4):404-417.
4. Carleton M. Menopause: Irish Women's Voices. *J of Obstetric, Gynaecologic & Neonatal Nursing*. 2000;29(4):397-404.
5. Diekx AA. Psychological aspects of menopause management. *BEST PRACT RES CL EN*. 2003;17(1):17-31.
6. Doherty L, Markovic N, Gorbars T. Patterns of smoking and menopause-specific quality of life: smoking duration matters more. *Behavioral Medicine*. 2020;5:1-11.
7. Freeman RW, et al. Risk of long-term hot flashes after natural menopause: evidence from the Penn Chariton Aging Study cohort. *Menopause*. 2014;21(10):104-102.
8. Gold EB, Guthrie A, Kelly N, et al. Longitudinal analysis of the association between vasomotor symptoms and neurocognitive across the menopause transition study of women's health across the nation. *Am J Public Health*. 2016;106(11):1771-1776.
9. Goodman N, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Menopause. *Endocrine Practice*. 2011;17:1-25.
10. Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. *Women's Health*. 2000;6(2):127-133.
11. Grunfeld GA, Stanfield B, Huang M, et al. Changes in body composition and weight during the menopause transition. *JG Insights*. 2019;4(5).
12. Maki PM, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. *Menopause*. 2018;25(10):1089-1095.
13. Melby MK, et al. Methods used in cross-cultural comparisons of vasomotor symptoms and their determinants. *Maturitas*. 2011;79(2):110-119.
14. Nemat M, et al. Social Determinants of Health in Menopause: An Integrative Review. *International Journal of Women's Health*. 2015;11:637-647.
15. Newhouse LM, Mennel M, Rayburn K, Sebbeh G, Yenka L. SMIs for Vasomotor Symptoms of Menopause. *Am Fam Physician*. 2022;105(6):630-631.
16. Obermayer CM. Menopausal stress: culture's a review of the evidence. *MENOPAUSE*. 2000;7(3):284-292.
17. Shea AK, et al. Guidelines No. 422: Menopausal Mood, Sleep, and Cognition. *Journal of Obstetrics and Gynaecology Canada*. 2013;43(11):1116-1123a1111.
18. Shifren JL, et al. The North American Menopause Society Recommendations for Clinical Care of Midlife Women. *Menopause*. 2014;21(10).
19. Stewart DE. Menopause in Highland Guatemala Mayan women. *Maturitas*. 2003;49(4):291-297.
20. Talalukher V. Menopause Transition: Physiology and symptoms. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2022;85:3-7.

